Last edition
News about Market
Boan Biotech's Dulaglutide Biosimilar 'Boyouping' Approved for Marketing in China
Boan Biotech announced that China’s National Medical Products Administration (NMPA) has granted marketing approval to its Boyouping (dulaglutide injection), indicated for glycemic control in adults with type 2 diabetes mellitus.
Market | 11/08/2025 | By Dineshwori | 737
Wockhardt Q1 Loss Widens to INR 108 Crore on US Subsidiary Liquidation
The loss was mainly driven by a INR 97 crore goodwill impairment following the company’s permanent exit from the US generics market and the voluntary liquidation of its Delaware-based subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC.
Market | 11/08/2025 | By Darshana | 324
While the number of deals was lower than the 12-month average of 95, the total deal value was significantly higher than the USD 13.2 billion average recorded between July 2024 and June 2025.
Market | 08/08/2025 | By Darshana | 284
Eli Lilly to Divest New Jersey Plant Amidst USD 27 Billion U.S. Manufacturing Expansion
As Eli Lilly advances its ambitious USD 27 billion investment plan to establish four new manufacturing facilities in the United States, the company has confirmed plans to sell its existing production site in Branchburg, New Jersey—a facility that has faced regulatory scrutiny in the past.
Market | 07/08/2025 | By Darshana | 747
Novo Nordisk Reports 18% H1 Sales Growth, Lowers H2 Outlook for Wegovy and Ozempic
Novo Nordisk has announced its financial results for the first half of 2025, ending June 30, with sales rising 18 percent at constant exchange rates (CER) to DKK 154.9 billion (USD 24.78 billion).
Market | 06/08/2025 | By Dineshwori | 1997
Pfizer Raises 2025 Profit Forecast After Strong Q2; Adjusted EPS Seen at USD 2.90-3.10
Pfizer has raised its full-year adjusted earnings per share (EPS) guidance to a range of USD 2.90–3.10, up from its prior outlook of USD 2.80–3.00, following strong second-quarter results that beat market expectations.
Market | 06/08/2025 | By Darshana | 281
US Tariffs Pose Serious Challenges for India's Key Export Sectors, Including Pharma: GlobalData
GlobalData has warned that the US tariffs, coupled with penalties linked to India’s dealings with Russian energy and military supplies, could pose serious challenges for key export sectors, including electronics, pharmaceuticals, automobiles, and textiles.
Market | 05/08/2025 | By Dineshwori | 558
India's Pharma Sector Attracts Over INR 2,450 Crore in July, Driven by Late-Stage Mega Deals
India’s pharmaceutical sector raised USD 294 million (approximately INR 2,450 crore) across 18 deals in July 2025, according to data from Tracxn.
Market | 04/08/2025 | By Darshana | 663
Despite the dip in profit, the company recorded a 9.5% rise in total revenue from operations, reaching INR 13,851.4 crore, up from INR 12,652.75 crore a year earlier. This growth was supported by solid performance across geographies, according to the company.
Market | 01/08/2025 | By Darshana | 362
GSK Q2 Sales Hit GBP 8 Billion, Driven Mainly by Specialty Medicines
GSK has delivered robust second-quarter 2025 results, fueled primarily by strong growth in its Specialty Medicines portfolio.
Market | 31/07/2025 | By Dineshwori | 495
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy